Company Profile
Qiagen N.V. Stock Price, News & Analysis
- Ticker:
- QGEN
- Exchange:
- NYSE
- Sector:
- MedTech
- Location:
- Netherlands and listed in the U
Stock performance
41.08 USD (-0.70%)
Close
Last updated: July 27, 2026
7.36B USD
Market cap
Why the stock is moving
As of Jul 27, 2026, QGEN closed down 0.70% at $41.08. No new same-company headline was identified in the current news window.
Company overview
Business overview
Qiagen is a global diagnostics and life sciences tools company focused on sample and assay technologies, molecular testing, and research workflows. Its products support research, clinical diagnostics, and applied testing.
Geographic Base and Sector Classification
Headquartered in the Netherlands and listed in the U.S. as an ADR, Qiagen has a broad international footprint. It sits in diagnostics and life sciences infrastructure rather than therapeutics.
Business Model Characteristics
The company generates revenue through consumables, assays, instrumentation, and related workflow solutions. Investors focus on molecular testing demand, lab activity, and the stability of recurring product usage.
Position Within the Biotechnology Landscape
Qiagen sits in the biotech tools and diagnostics layer. It is not a drug developer, but it is important to the ecosystem because it enables research and testing across the life sciences stack.
Future catalysts
QIAGEN’s catalysts are sample-prep and oncology-assay demand, plus continued execution in a more selective diagnostics market. This matters because it helps show whether the company can turn its current footprint into a cleaner earnings profile. Better execution here can matter even before a new product or trial headline lands.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results
BRLI · Source: Bio-Reference Laboratories
- 02
bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung
BIAF · Source: bioAffinity Technologies, Inc.
- 03
OPKO Health to Report Second Quarter 2026 Financial Results on July 27, 2026
BRLI · Source: Bio-Reference Laboratories
- 04
Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026
DGX · Source: Quest Diagnostics
- 05
bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD
BIAF · Source: bioAffinity Technologies, Inc.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Qiagen N.V. (QGEN)?
Qiagen N.V. (QGEN) most recently closed at 41.08 USD, a -0.70% move versus the previous session.
What is the market cap of Qiagen N.V. (QGEN)?
Qiagen N.V. currently has a market capitalization of 7.36B USD on BioPharmSignal.
What does Qiagen N.V. do?
Qiagen is a global diagnostics and life sciences tools company focused on sample and assay technologies, molecular testing, and research workflows. Its products support research, clinical diagnostics, and applied testing.
On which exchange is QGEN stock listed?
Qiagen N.V. (QGEN) is associated with NYSE, Netherlands and listed in the U, MedTech.
What is Qiagen?
QIAGEN’s catalysts are sample-prep and oncology-assay demand, plus continued execution in a more selective diagnostics market.
Which conditions is Qiagen N.V. targeting with Qiagen?
Qiagen N.V. is associated with oncology based on its company overview and current catalyst commentary.
How does Qiagen N.V. describe recent progress with Qiagen?
QIAGEN’s catalysts are sample-prep and oncology-assay demand, plus continued execution in a more selective diagnostics market.
What is This?
This matters because it helps show whether the company can turn its current footprint into a cleaner earnings profile.